<SEC-DOCUMENT>0001104659-23-068347.txt : 20230606
<SEC-HEADER>0001104659-23-068347.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230606080838
ACCESSION NUMBER:		0001104659-23-068347
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230602
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230606

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Milne Jill C.
		CENTRAL INDEX KEY:			0001644246

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		23994937

	MAIL ADDRESS:	
		STREET 1:		C/O CATABASIS PHARMACEUTICALS, INC.
		STREET 2:		ONE KENDALL SQ., BLDG. 1400E, STE.B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 1400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 1400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2317752-13_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0407</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-06-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001454789</issuerCik>
        <issuerName>Astria Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ATXS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001644246</rptOwnerCik>
            <rptOwnerName>Milne Jill C.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ASTRIA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>75 STATE STREET, SUITE 1400</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02109</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>CEO and President</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.36</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-06-02</value>
                <footnoteId id="F1"/>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>275000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-01-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>275000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>275000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the &quot;Company&quot;) Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the &quot;Stock Plan Amendment Proposal&quot;). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023.</footnote>
        <footnote id="F2">This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 275,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Ben Harshbarger, as attorney-in-fact for Jill C. Milne</signatureName>
        <signatureDate>2023-06-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>tm2317752d13_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-right: 0; margin-bottom: 0"><B>Exhibit 24</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><IMG SRC="tm2317752d13_ex24img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>75 State Street, Suite 1400, Boston MA
02109</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LIMITED POWER OF ATTORNEY</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>FOR SECTION 16 REPORTING OBLIGATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Know all by these
presents, that the undersigned hereby makes, constitutes and appoints each of Ben Harshbarger and Noah Clauser signing singly and each
acting individually, as the undersigned&#8217;s true and lawful attorney-in-fact with full power and authority as hereinafter described
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;execute
for and on behalf of the undersigned, in the undersigned&#8217;s capacity as an officer of Catabasis Pharmaceuticals, Inc. (the &#8220;Company&#8221;),
Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder (the &#8220;Exchange Act&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute
any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with
the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) and any stock exchange or similar authority, including without
limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain
access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;seek or obtain, as the undersigned&#8217;s representative and on the undersigned&#8217;s behalf, information regarding transactions in
the Company&#8217;s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned
hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release
of information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such attorney-in-fact&#8217;s discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The undersigned hereby
grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact&#8217;s substitute or substitutes, shall lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving
in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of
the undersigned&#8217;s responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the
Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned&#8217;s responsibility to comply with the requirement
of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or
liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This Power of Attorney
shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned&#8217;s
holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 1pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of  June 3, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 1pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Sign:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Jill C. Milne</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jill C. Milne</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2317752d13_ex24img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2317752d13_ex24img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, +,# 2(  A$! Q$!_\0
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M8@#&4#*Y(]0:BUOP_J5QK>IMJ=JE[;27-BQD737EB=5CG!_=!B6P67//!(H
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&*** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
